Today’s biopharma news highlights how new data could reduce treatment burden, improve excipient information sharing, and shape future options for patients with difficult-to-treat cancers.
|Articles|March 1, 2014
- BioPharm International-03-01-2014
- Volume 27
- Issue 3
BioPharm International, March 2014 Issue (PDF)
Click the title above to open the BioPharm International March 2014 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 12 years ago
Manufacturers Struggle with Breakthrough Drug Developmentover 12 years ago
Regulators Get Tough on Corruption in Chinaover 12 years ago
UPLC System for Nano- to Microscale Separationsover 12 years ago
Predicting Lyophilization Performanceover 12 years ago
ALpHA G Capsule Filter for Single-Use Systemsover 12 years ago
European Union Packaging Safety Features Come into EffectAdvertisement
Related to this article
Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.
IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.
Insulin efsitora alfa-gobe (Onswik) cuts injections from 365 to 52 a year for adults with type 2 diabetes, per its new FDA approval.
Genentech is paying Earendil Labs $55 million upfront in a deal worth over $1.5 billion to develop bispecific antibodies for hard-to-treat cancers.
Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
AstraZeneca's sBLA for durvalumab combined with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer, based on the Phase 3 VOLGA trial, has a PDUFA date expected in the fourth quarter of 2026.
Advertisement
Advertisement